Gregory Storch, MD

Gregory is the Ruth L. Siteman Professor of Pediatrics and Professor of Medicine and of Molecular Microbiology at Washington University School of Medicine and past chief of the Divisions of Pediatric Infectious Diseases and Pediatric Laboratory Medicine. He received his AB degree from Harvard College and his MD from NYU School of Medicine. He completed internship and residency in internal medicine at the Jewish Hospital of St. Louis, was an Epidemic Intelligence Service Officer for the Centers for Disease Control in the Louisiana Department of Health in New Orleans, and an infectious disease fellow at Washington University. He joined the Washington University faculty in 1981. He is the co-Medical Director of Project ARK, a pediatric HIV service organization affiliated with the Washington University Department of Pediatrics. Storch is past president of the Pan-American Society for Clinical Virology. He currently serves as Chair of the Finance Committee of the Pediatric Infectious Diseases Society. He is also an Associate Editor of the Journal of the Pediatric Infectious Diseases Society. Dr. Storch’s research interests are in molecular diagnosis of infectious diseases and infectious disease genomics. He currently serves as Research Integrity Officer for Washington University.

Yael P. Mosse, MD

Yael P. Mosse is a tenured Associate Professor at The Children’s Hospital of Philadelphia and the Perelman School of Medicine of the University of Pennsylvania. Her clinical and research specialty is neuroblastoma, a cancer that starts in the nerve tissues of infants and young children. She received her M.D. from the Sackler School of Medicine, Tel Aviv, Israel, in 1997, joining the Children’s Hospital residency program that year, followed by fellowship training at the same hospital starting in 2000. Dr. Mosse trained in the laboratory of John Maris, MD and now has her own independent NIH-funded research program where we investigate the hereditary predisposition and progression of neuroblastoma with a focus on drug development. The broad goal of her research program is to improve cure rates for the childhood cancer neuroblastoma by discovering the genetic basis of the disease and translating rationale therapeutic opportunities that are more effective and less toxic to the clinic.

David Wheeler, PhD

David Wheeler, PhD, received his Bachelor of Science in Biochemistry and Zoology from the University of Maryland and Ph.D in Molecular Genetics in Cancer Virology at George Washington University. His Postdoctoral research was in behavioral genetics of fruitflies at Brandeis University with Dr. Jeffrey Hall. There, he and his colleagues cloned the period locus, the first gene with an established role in regulating complex behavior (circadian rhyhthms) in any organism. His work laid the foundation for the Nobel Prize in Physiology and Medicine awarded to Drs. Hall, Rosbash and Young in 2017. As Director of Cancer Genomics in the Human Genome Sequencing Center at Baylor College of Medicine, he has contributed ground-breaking research into the role of somatic mutation in tumorigenesis through DNA and RNA sequencing in large-scale cancer cohorts. He was a member of the Executive Committee of the The Cancer Genome Atlas and a member of the International Cancer Genome Consortium and serves on the editorial board of Genome Research. Dr. Wheeler’s research focues on deciphering the role of somatic alteration in cancer initiation and progression, and in identifying the genetic mechanisms that give rise to drug sensitivity and resistance phenotypes in cancer patients.

Elaine B. Spector, PhD

She is a Professor of Pediatrics in the Division of Genetics and Metabolism at the University of Colorado School of Medicine, Denver, CO. Dr. Spector graduated from Washington University in 1970 and completed her PhD thesis in 1974 in the Department of Human Genetics at the University of Michigan with an emphasis in cytogenetics and biochemical genetics. Dr. Spector completed a postdoctoral fellowship in biochemical genetics at the University of California San Diego and then performed research on inherited disorders of the urea cycle at the University of California Los Angeles for 8 years beginning in 1976. In 1985 while at UCLA Dr. Spector established one of the first Molecular Diagnostic Laboratories in the United States. After moving to the University of Colorado School of Medicine Dr. Spector has been the director of both clinical cytogenetics and clinical molecular genetics laboratories. Studies in the molecular genetics laboratory have focused on rare disorders with an emphasis on Fragile X syndrome, nonketotic hyperglycinemia (NKH), Glutaric Acidemia Type I (GA1), VLCAD deficiency, and albinism. Dr. Spector is a fellow of the American College of Medical Genetics and Genomics and served on it’s Board of Directors. Dr. Spector is currently a member of the Board of Directors of the American Board of Medical Genetics and Genomics (ABMGG).

Jonathan Liu, PhD

Jonathan Liu, received his Ph.D. in Chemistry from University of Missouri-Columbia. He had developed technologies related to the multiplexed capillary electrophoresis during Human Genome Project. His key inventions were in optical detection and Pop7 gels. He founded SoftGenetics in 2003, and their products of Mutation Surveyor, GeneMarker and NextGENe are widely used in the world.

AMP Global - Zehir

Ahmet Zehir, PhD

Is currently the Director of Clinical Bioinformatics and Assistant Attending Bioinformatician in the Molecular Diagnostics Service in the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSKCC). He leads a large team of computational biologists and software engineers. He is responsible from overseeing development of Next-Generation Sequencing (NGS) data analysis pipelines and clinical validation of NGS assays. Additionally, he trains clinical bioinformatics analysts and molecular pathology fellows in computational methods for analyzing sequencing data and reviewing pipeline results. He played a major role in developing the analysis pipeline for MSK-IMPACT assay and obtaining NYS-DOH approval as well as FDA authorization. His team also develops software solutions for the molecular laboratory which helps with automated data analysis of test results, automatic report generation and sharing the reports within the hospital systems with the clinicians and researchers. He and his colleagues have also implemented MSI-sensor analysis for a wide variety of tumor types and assessment of tumor mutational burden for solid tumors. His current research interests are focused on two main areas: discovery and characterization of clonal hematopoiesis in patients with advanced disease; discovery of genetic biomarkers related to cancer initiation and progression He is also in charge of advancing new technology to improve the NGS data analysis results and expanding the landscape of NGS results.